GSK released a similar statement last week after a Delaware state court judge allowed Zantac claims to continue in that jurisdiction. The company promised an appeal in that matter and to fight the Connecticut claims.
“Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer,” the company said in a statement to Law360 on Tuesday. “GSK will continue to vigorously defend itself against all claims.”
In a 2022 statement, Pfizer said it only sold Zantac between 1998 and 2006, more than a decade before the drug was withdrawn from the market in 2019 and 2020.
“Pfizer has significant defenses to this litigation and there are significant legal and factual issues that remain to be addressed by the courts,” the company said in 2022. “Pfizer also has substantial indemnification claims against others, which have been acknowledged by several manufacturers in their disclosures.”
